Journal SAM (February 2012): Modern Nuclear Imaging for Paragangliomas: Beyond SPECT

MOC Part II SAM Modules

Journal SAM:  Modern Nuclear Imaging for Paragangliomas:  Beyond SPECT

Member Fee:  Free
Non-Member Fee:  $90.00

Release Date:  2/1/2012
Expiration Date:  2/28/2015

Continuing Education Credit Information

The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment.   2.5 SAMs have been awarded for this activity.

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI designates this enduring material for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.


On successful completion of this activity, participants should be able to: 

  1. The best nuclear imaging procedures to detect pheochromocytomas/paragangliomas according to the clinical situation( e.g., sporadic vs. hereditary; primary vs. metastatic; sympathetic vs. parasympathic).
  2. The differences in th ephenotypic information obtained by various PET tracers.

Target Audience

The LLSAP is designed for all nuclear medicine specialists and other physicians, pharmacists and technologists who practice diagnostic and/or therapeutic nuclear medicine.

Faculty Disclosure(s)

David Taïeb*1, Hartmut Neumann*2, Domenico Rubello3, Adil Al-Nahhas4, Benjamin Guillet1, and Elif Hindié5

1Department of Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, Marseille, France; 2Preventive Medicine Unit, Department of Medicine, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany; 3Department of Nuclear Medicine, PET/CT Centre, Radiology, Medical Physics, ?Santa Maria della Misericordia? Hospital, Rovigo, Italy; 4Department of Nuclear Medicine, Hammersmith Hospital, London, United Kingdom; and 5Department of Nuclear Medicine, Haut-Lévêque Hospital, University of Bordeaux-2, Bordeaux, France
*Contributed equally to this work.

In accordance with ACCME Revised Standards for Commercial Support and SNM Conflict-of-Interest Policy, the authors have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.